Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-sialyl-Tn antibody-drug conjugate
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-sialyl-Tn antibody-drug conjugate (ADC) is a preclinical biologic therapeutic developed by Siamab Therapeutics. It consists of a humanized monoclonal antibody targeting the tumor-associated carbohydrate antigen (TACA) Sialyl-Tn (STn), also known as CD175s or the Sialyl-Thomsen-nouveau antigen. The antibody is conjugated to the cytotoxic payload monomethyl auristatin E (MMAE), a potent anti-mitotic agent that inhibits tubulin polymerization. STn is highly expressed on the surface of various epithelial cancers, including ovarian, colorectal, breast, prostate, and pancreatic tumors, but is rarely found in normal adult tissues. The ADC is designed to selectively deliver MMAE to STn-expressing cancer cells, exploiting the tumor-specificity of the antigen to minimize off-target toxicity and potentially overcome immune suppression and chemoresistance associated with STn expression.
- Other names
- anti-Sialyl-Tn ADCanti-STn antibody-drug conjugate
02
Targets
STn-MUC1 (Sialyl-Tn-MUC1)
Beyond the preview
Go deeper on anti-sialyl-Tn antibody-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-sialyl-Tn antibody-drug conjugate.